Literature DB >> 11044454

Overexpression of a mammalian ethanolamine-specific kinase accelerates the CDP-ethanolamine pathway.

A Lykidis1, J Wang, M A Karim, S Jackowski.   

Abstract

Ethanolamine kinase (EKI) is the first committed step in phosphatidylethanolamine (PtdEtn) biosynthesis via the CDP-ethanolamine pathway. We identify a human cDNA encoding an ethanolamine-specific kinase EKI1 and the structure of the EKI1 gene located on chromosome 12. EKI1 overexpression in COS-7 cells results in a 170-fold increase in ethanolamine kinase-specific activity and accelerates the rate of [3H]ethanolamine incorporation into PtdEtn as a function of the ethanolamine concentration in the culture medium. Acceleration of the CDP-ethanolamine pathway does not result in elevated cellular PtdEtn levels, but rather the excess PtdEtn is degraded to glycerophosphoethanolamine. EKI1 has negligible choline kinase activity in vitro and does not influence phosphatidylcholine biosynthesis. Acceleration of the CDP-ethanolamine pathway also does not change the rate of PtdEtn formation via the decarboxylation of phosphatidylserine. The data demonstrate the existence of separate ethanolamine and choline kinases in mammals and show that ethanolamine kinase can be a rate-controlling step in PtdEtn biosynthesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11044454     DOI: 10.1074/jbc.M008794200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

1.  The phosphatidylethanolamine biosynthesis pathway provides a new target for cancer chemotherapy.

Authors:  Yuan Guan; Xinyu Chen; Manhong Wu; Wan Zhu; Ahmed Arslan; Saori Takeda; Mindie H Nguyen; Ravindra Majeti; Dan Thomas; Ming Zheng; Gary Peltz
Journal:  J Hepatol       Date:  2019-11-22       Impact factor: 25.083

2.  Molecular causes of elevated phosphoethanolamine in breast and pancreatic cancer cells.

Authors:  Tariq Shah; Balaji Krishnamachary; Flonne Wildes; Jannie P Wijnen; Kristine Glunde; Zaver M Bhujwalla
Journal:  NMR Biomed       Date:  2018-06-21       Impact factor: 4.044

3.  Integrated microRNA-mRNA analysis of coronary artery disease.

Authors:  Fei Chen; Xin Zhao; Juan Peng; LinPing Bo; Bing Fan; Duan Ma
Journal:  Mol Biol Rep       Date:  2014-06-10       Impact factor: 2.316

4.  Molecular identification of hydroxylysine kinase and of ammoniophospholyases acting on 5-phosphohydroxy-L-lysine and phosphoethanolamine.

Authors:  Maria Veiga-da-Cunha; Farah Hadi; Thomas Balligand; Vincent Stroobant; Emile Van Schaftingen
Journal:  J Biol Chem       Date:  2012-01-12       Impact factor: 5.157

Review 5.  Surfactant phospholipid metabolism.

Authors:  Marianna Agassandian; Rama K Mallampalli
Journal:  Biochim Biophys Acta       Date:  2012-09-29

Review 6.  Choline metabolism-based molecular diagnosis of cancer: an update.

Authors:  Kristine Glunde; Marie-France Penet; Lu Jiang; Michael A Jacobs; Zaver M Bhujwalla
Journal:  Expert Rev Mol Diagn       Date:  2015-04-28       Impact factor: 5.225

7.  Elimination of the CDP-ethanolamine pathway disrupts hepatic lipid homeostasis.

Authors:  Roberta Leonardi; Matthew W Frank; Pamela D Jackson; Charles O Rock; Suzanne Jackowski
Journal:  J Biol Chem       Date:  2009-08-07       Impact factor: 5.157

8.  Physiological consequences of disruption of mammalian phospholipid biosynthetic genes.

Authors:  Dennis E Vance; Jean E Vance
Journal:  J Lipid Res       Date:  2008-10-27       Impact factor: 5.922

9.  Control of the CDPethanolamine pathway in mammalian cells: effect of CTP:phosphoethanolamine cytidylyltransferase overexpression and the amount of intracellular diacylglycerol.

Authors:  Onno B Bleijerveld; Wil Klein; Arie B Vaandrager; J Bernd Helms; Martin Houweling
Journal:  Biochem J       Date:  2004-05-01       Impact factor: 3.857

10.  Differential role of human choline kinase alpha and beta enzymes in lipid metabolism: implications in cancer onset and treatment.

Authors:  David Gallego-Ortega; Ana Ramirez de Molina; Maria Angeles Ramos; Fatima Valdes-Mora; Maria Gonzalez Barderas; Jacinto Sarmentero-Estrada; Juan Carlos Lacal
Journal:  PLoS One       Date:  2009-11-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.